| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |


From the Institute of Pathology,*
Universitätsklinikum Charité, Medizinische Fakultät
der Humboldt-Universität Berlin, Berlin, Germany; the Clinic of
Surgery and Surgical Oncology,
Robert-Rössle Klinik, Berlin, Germany; and the Department of
Obstetrics and Gynecology,
Baylor College of
Medicine, Houston Texas
Caveolae are plasma membrane microdomains that have been implicated
in the regulation of several intracellular signaling pathways. Previous
studies suggest that caveolin-1, the main structural protein of
caveolae, could function as a tumor suppressor. Caveolin-1 is
highly expressed in terminally differentiated mesenchymal cells
including adipocytes, endothelial cells, and smooth
muscle cells. To study whether caveolin-1 is a possible tumor
suppressor in human mesenchymal tumors, we have analyzed the
expression using immunohistochemistry in normal mesenchymal
tissues, 22 benign and 79 malignant mesenchymal tumors.
Caveolin-1 was found to be expressed in fibromatoses,
leiomyomas, hemangiomas, and lipomas at high levels
comparable to normal mesenchymal tissues. The expression of caveolin-1
was slightly reduced in four of six well-differentiated liposarcomas
and strongly reduced or lost in three of three fibrosarcomas,
17 of 20 leiomyosarcomas, 16 of 16 myxoid/round
cell/pleomorphic liposarcomas, five of eight
angiosarcomas, 15 of 18 malignant fibrous
histiocytomas, and eight of eight synovial sarcomas. The
immunohistochemical findings were confirmed by Western blot analysis in
a number of tumors. High levels of both the 24-kd [
]- and the
21-kd [ß]-isoform of caveolin-1 were detected in the nontumorigenic
human fibroblast cell line IMR-90. In contrast, in HT-1080
human fibrosarcoma cells, caveolin-1 is strongly
down-regulated. We show that the [
]-isoform of caveolin-1 is
potently up-regulated in HT-1080 cells by inhibition of the
mitogen-activated protein kinase-signaling pathway with the specific
inhibitor PD 98059, whereas the specific inhibitor of DNA
methylation 5-aza-2'-deoxycytidine only marginally up-regulates
caveolin-1. In addition, re-expression of caveolin-1 in HT-1080
fibrosarcoma cells potently inhibited colony formation. From these we
conclude that caveolin-1 is likely to act as a tumor suppressor gene in
human sarcomas.
This article has been cited by other articles:
![]() |
V. A. Torres, J. C. Tapia, D. A. Rodriguez, A. Lladser, C. Arredondo, L. Leyton, and A. F. G. Quest E-Cadherin Is Required for Caveolin-1-Mediated Down-Regulation of the Inhibitor of Apoptosis Protein Survivin via Reduced {beta}-Catenin-Tcf/Lef-Dependent Transcription Mol. Cell. Biol., November 1, 2007; 27(21): 7703 - 7717. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Burgermeister, X. Xing, C. Rocken, M. Juhasz, J. Chen, M. Hiber, K. Mair, M. Shatz, M. Liscovitch, R. M. Schmid, et al. Differential Expression and Function of Caveolin-1 in Human Gastric Cancer Progression Cancer Res., September 15, 2007; 67(18): 8519 - 8526. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cantiani, M. C. Manara, C. Zucchini, P. De Sanctis, M. Zuntini, L. Valvassori, M. Serra, M. Olivero, M. F. Di Renzo, M. P. Colombo, et al. Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling Cancer Res., August 15, 2007; 67(16): 7675 - 7685. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Tirado, S. Mateo-Lozano, J. Villar, L. E. Dettin, A. Llort, S. Gallego, J. Ban, H. Kovar, and V. Notario Caveolin-1 (CAV1) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells. Cancer Res., October 15, 2006; 66(20): 9937 - 9947. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Torres, J. C. Tapia, D. A. Rodriguez, M. Parraga, P. Lisboa, M. Montoya, L. Leyton, and A. F. G. Quest Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin J. Cell Sci., May 1, 2006; 119(9): 1812 - 1823. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, et al. CD99 Acts as an Oncosuppressor in Osteosarcoma Mol. Biol. Cell, April 1, 2006; 17(4): 1910 - 1921. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schwencke, R. C. Braun-Dullaeus, C. Wunderlich, and R. H. Strasser Caveolae and caveolin in transmembrane signaling: Implications for human disease Cardiovasc Res, April 1, 2006; 70(1): 42 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rennebeck, M. Martelli, and N. Kyprianou Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis? Cancer Res., December 15, 2005; 65(24): 11230 - 11235. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Miotti, A. Tomassetti, I. Facetti, E. Sanna, V. Berno, and S. Canevari Simultaneous Expression of Caveolin-1 and E-Cadherin in Ovarian Carcinoma Cells Stabilizes Adherens Junctions through Inhibition of src-Related Kinases Am. J. Pathol., November 1, 2005; 167(5): 1411 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Williams and M. P. Lisanti Caveolin-1 in oncogenic transformation, cancer, and metastasis Am J Physiol Cell Physiol, March 1, 2005; 288(3): C494 - C506. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Aldred, Y. Huang, S. Liyanarachchi, N. S. Pellegata, O. Gimm, S. Jhiang, R. V. Davuluri, A. de La Chapelle, and C. Eng Papillary and Follicular Thyroid Carcinomas Show Distinctly Different Microarray Expression Profiles and Can Be Distinguished by a Minimum of Five Genes J. Clin. Oncol., September 1, 2004; 22(17): 3531 - 3539. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Aldred, M. E. Ginn-Pease, C. D. Morrison, A. P. Popkie, O. Gimm, C. Hoang-Vu, U. Krause, H. Dralle, S. M. Jhiang, C. Plass, et al. Caveolin-1 and Caveolin-2,Together with Three Bone Morphogenetic Protein-related Genes, May Encode Novel Tumor Suppressors Down-Regulated in Sporadic Follicular Thyroid Carcinogenesis Cancer Res., June 1, 2003; 63(11): 2864 - 2871. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Labrecque, I. Royal, D. S. Surprenant, C. Patterson, D. Gingras, and R. Beliveau Regulation of Vascular Endothelial Growth Factor Receptor-2 Activity by Caveolin-1 and Plasma Membrane Cholesterol Mol. Biol. Cell, January 1, 2003; 14(1): 334 - 347. [Abstract] [Full Text] |
||||
![]() |
H. Lee, D. S. Park, B. Razani, R. G. Russell, R. G. Pestell, and M. P. Lisanti Caveolin-1 Mutations (P132L and Null) and the Pathogenesis of Breast Cancer : Caveolin-1 (P132L) Behaves in a Dominant-Negative Manner and Caveolin-1 (-/-) Null Mice Show Mammary Epithelial Cell Hyperplasia Am. J. Pathol., October 1, 2002; 161(4): 1357 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Wiechen, L. Diatchenko, A. Agoulnik, K. M. Scharff, H. Schober, K. Arlt, B. Zhumabayeva, P. D. Siebert, M. Dietel, R. Schafer, et al. Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene Am. J. Pathol., November 1, 2001; 159(5): 1635 - 1643. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |